MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

Начало・Списък с акции・Vaxcyte Inc

Vaxcyte Inc

Затворен

СекторЗдравеопазване

61.76 1.86

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

59.85

Максимум

63.2

Ключови измерители
By Trading Economics
Приходи	-34M -247M
EPS	-1.8
Служители	507
EBITDA	-25M -235M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+84.59% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	36M 8.7B
Предишно отваряне	59.9
Предишно затваряне	61.76

Настроения в новините

By Acuity

50%

154 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

28.09 / 34 Подкрепа & съпротива

Vaxcyte Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.04.2026 г., 23:25 ч. UTC

Значими събития в новините

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13.04.2026 г., 22:45 ч. UTC

Значими събития в новините

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13.04.2026 г., 18:03 ч. UTC

Печалби

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13.04.2026 г., 23:58 ч. UTC

Печалби

Review & Preview: Earnings Time -- Barrons.com

13.04.2026 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13.04.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13.04.2026 г., 23:20 ч. UTC

Пазарно говорене

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13.04.2026 г., 23:01 ч. UTC

Печалби

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13.04.2026 г., 23:01 ч. UTC

Печалби

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13.04.2026 г., 23:01 ч. UTC

Печалби

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13.04.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13.04.2026 г., 21:26 ч. UTC

Значими събития в новините

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13.04.2026 г., 21:23 ч. UTC

Печалби

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13.04.2026 г., 21:16 ч. UTC

Печалби

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

13.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

13.04.2026 г., 20:34 ч. UTC

Печалби

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13.04.2026 г., 20:34 ч. UTC

Печалби

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13.04.2026 г., 20:34 ч. UTC

Печалби

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13.04.2026 г., 19:59 ч. UTC

Пазарно говорене

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13.04.2026 г., 19:50 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13.04.2026 г., 19:27 ч. UTC

Пазарно говорене

Значими събития в новините

Correction to Precious Metals Market Talk on April 9

13.04.2026 г., 19:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13.04.2026 г., 18:59 ч. UTC

Пазарно говорене

Значими събития в новините

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13.04.2026 г., 18:59 ч. UTC

Пазарно говорене

Значими събития в новините

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13.04.2026 г., 18:43 ч. UTC

Пазарно говорене

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Vaxcyte Inc Прогноза

Ценова цел

By TipRanks

84.59% нагоре

12-месечна прогноза

Среден 112.38 USD 84.59%

Висок 163 USD

Нисък 67 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Vaxcyte Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Vaxcyte Inc през последните 3 месеца.

Техническа оценка

By Trading Central

28.09 / 34Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Настроение

By Acuity

154 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.